StockNews.com Lowers Dynavax Technologies (NASDAQ:DVAX) to Hold

Dynavax Technologies (NASDAQ:DVAX) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

Other research analysts also recently issued reports about the company. The Goldman Sachs Group assumed coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 target price on the stock. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.

Dynavax Technologies Price Performance

Shares of DVAX traded down $0.06 on Wednesday, hitting $11.43. The company’s stock had a trading volume of 2,549,852 shares, compared to its average volume of 1,944,944. The company has a market capitalization of $1.50 billion, a PE ratio of -190.47 and a beta of 1.26. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96. Dynavax Technologies has a fifty-two week low of $10.06 and a fifty-two week high of $15.15. The company has a 50 day moving average price of $12.41 and a 200 day moving average price of $13.35.

Insider Activity at Dynavax Technologies

In related news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 9.31% of the stock is owned by corporate insiders.

Institutional Trading of Dynavax Technologies

A number of large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in Dynavax Technologies by 9.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,081,789 shares of the biopharmaceutical company’s stock worth $15,978,000 after purchasing an additional 95,690 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Dynavax Technologies by 20.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock worth $20,083,000 after purchasing an additional 231,731 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Dynavax Technologies by 8.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,820 shares of the biopharmaceutical company’s stock worth $1,194,000 after purchasing an additional 6,339 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Dynavax Technologies by 4.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 36,484 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 1,652 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Dynavax Technologies by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock worth $135,100,000 after purchasing an additional 270,730 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.